TRPM8 and posterior cortical atrophy: As first step in the generation of an in vitro platform where testing the impact of TRPM8 pharmacology on first-line clinical protocols adopted for the treatment of locally advanced/high-risk PCa, immortalized androgen sensitive RWPE-1 (Supplementary Fig. S4) and hormone naïve lymph node metastatic LNCaPFGC cell lines have been genetically engineered to model different levels of TRPM8 expression.